The Unmet Need
Restless Legs Syndrome (RLS) is a neurological disorder affects the ability to fall and stay asleep for more than 10% of the western adult population, making it the second most common sleep disorder in the world. In the United States alone, more than 25 million adults suffer with symptoms of RLS; 8M of whom have severe symptoms that prevent them from being able to fall asleep more than 3 nights each week. These sensations of RLS are most prevalent at night, thus leading to sleep deprivation and its downstream consequences of depressed mood, irritability, forgetfulness, difficulty learning, and lack of motivation. As such, patients with RLS suffer from all the same downstream risks caused by sleep deprivation including clinical depression – a recent study shows RLS patients were nearly three times more likely to inflict self-harm.
Our first product (NTX100) aims to treat symptoms of moderate-severe Restless Legs Syndrome (RLS) and has won a “Breakthrough Device Designation (BDD)” from the US FDA, a first-in-class for a non-invasive medical device.
In The Press
Noctrix Health Announces Enrollment of First Patient in The RESTFUL Study and Publication of Positive Pilot Study Results
PLEASANTON, Calif., May 25, 2021 /PRNewswire/ — Noctrix Health, Inc. today announced that the first patient…
Noctrix Health granted FDA Breakthrough Device Designation for wearable Restless Legs Syndrome Therapy
SAN FRANCISCO, June 2, 2020 /PRNewswire/ — Noctrix Health, Inc., a privately held medical device company…
SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ — Noctrix Health, Inc., a private medical device company,…
Want to join a fast-paced, hybrid team that is looking to make a giant impact on the way medical devices are utilized in clinical practice? Join us!
NOTE: Any positions that we are actively recruiting for are listed below and all email enquires should be directed to email@example.com